AAAAAA

   
Results: 1-9 |
Results: 9
Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI Xanti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu
Authors: Schwaab, T Lewis, LD Cole, BF Deo, Y Fanger, MW Wallace, P Guyre, PM Kaufman, PA Heaney, JA Schned, AR Harris, RD Ernstoff, MS
Citation: T. Schwaab et al., Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI Xanti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu, J IMMUNOTH, 24(1), 2001, pp. 79-87
Asymptomatic QTc prolongation associated with quetiapine fumarate overdosein a patient being treated with risperidone
Authors: Beelen, AP Yeo, KTJ Lewis, LD
Citation: Ap. Beelen et al., Asymptomatic QTc prolongation associated with quetiapine fumarate overdosein a patient being treated with risperidone, HUM EXP TOX, 20(4), 2001, pp. 215-219
Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas
Authors: Pipas, JM Mitchell, SE Barth, RJ Vera-Gimon, R Rathmann, J Meyer, LP Wagman, RS Lewis, LD McDonnell, C Colacchio, TA Perez, RP
Citation: Jm. Pipas et al., Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas, INT J RAD O, 50(5), 2001, pp. 1317-1322
Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu
Authors: Lewis, LD Cole, BF Wallace, PK Fisher, JL Waugh, M Guyre, PM Fanger, MW Curnow, RT Kaufman, PA Ernstoff, MS
Citation: Ld. Lewis et al., Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu, J IMMUNOL M, 248(1-2), 2001, pp. 149-165
Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo
Authors: Wallace, PK Kaufman, PA Lewis, LD Keler, T Givan, AL Fisher, JL Waugh, MG Wahner, AE Guyre, PM Fanger, MW Ernstoff, MS
Citation: Pk. Wallace et al., Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo, J IMMUNOL M, 248(1-2), 2001, pp. 167-182
Visualization of intravenously administered contrast material in the CSF on fluid-attenuated inversion-recovery MR images: An in vitro and animal-model investigation
Authors: Mamourian, AC Hoopes, PJ Lewis, LD
Citation: Ac. Mamourian et al., Visualization of intravenously administered contrast material in the CSF on fluid-attenuated inversion-recovery MR images: An in vitro and animal-model investigation, AM J NEUROR, 21(1), 2000, pp. 105-111
Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction (vol 62, pg 464, 1997)
Authors: Lewis, LD Benin, A Szumlanski, CL Otterness, DM Lennard, L Weinshilboum, RM Nierenberg, DW
Citation: Ld. Lewis et al., Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction (vol 62, pg 464, 1997), CLIN PHARM, 67(4), 2000, pp. 431-431
Escalating multiple-dose safety and tolerance study of oral WR 6026 in HIV-infected subjects: AIDS clinical trials group 173
Authors: Petty, BG Black, JR Hendrix, CW Lewis, LD Basiakos, Y Feinberg, J Pattison, DG Hafner, R
Citation: Bg. Petty et al., Escalating multiple-dose safety and tolerance study of oral WR 6026 in HIV-infected subjects: AIDS clinical trials group 173, J ACQ IMM D, 21(1), 1999, pp. 26-32
Noradrenergic modulation of cognitive flexibility in problem solving
Authors: Beversdorf, DQ Hughes, JD Steinberg, BA Lewis, LD Heilman, KM
Citation: Dq. Beversdorf et al., Noradrenergic modulation of cognitive flexibility in problem solving, NEUROREPORT, 10(13), 1999, pp. 2763-2767
Risultati: 1-9 |